72 results about "Salmonella enterica" patented technology

The present invention relates to methods and compositions for identifying a pathogen. The inventions provide an antibody-based biosensor probe comprising (AUNT) in combination with a polymer-coated magnetic nanoparticle. In particular, a nanoparticle-based biosensor was developed for detection of Escherichia coli O157:H7 bacterium in food products. Further described are biosensors for detecting pathogens at low concentrations in samples. Even further, a gold nanoparticle-based electrochemical biosensor detection and amplification method for identifying the insertion element gene of Salmonella enterica Serovar Enteritidis is described. The present invention provides compositions and methods for providing a handheld potentiostat system for detecting pathogens outside of the laboratory. The AUNT biosensor system has applications detecting pathogens in food, water, beverages, clinical samples, and environmental samples.

A method for upgrading human food and animal feed, rendering harmless the contaminating mycotoxins, increasing protein and nucleotide content, providing immuno-modulation, enhancing flavor and palatability is proposed. The method comprises a food functional additive/supplement and feed additive based on yeast biomass processed to enhance the bioavailability and biological activity of its components using dry micron milling with optional agglomeration. The resulting product contains all biologically active components originally present in intact live yeast. Compared to existing practice, the new process is much faster, cheaper, less hardware demanding, less prone to microbial contamination, provides intact biopolymers and results in insoluble product fraction with high surface area. Human food and animal feed containing such additive improves weight gains, feed efficiency, resilience to mycotoxin contamination, improves immunological status, controls intestinal Salmonella and other bacteria and decreases mortality, especially at the young age, replacing antibiotics and growth promoters.

The invention relates to a compound gene chip for detecting salmonella serotype and a detection method thereof. salmonella paratyphi A, salmonella paratyphi B, salmonella typhimurium, salmonella paratyphi C, salmonella typhisuis, salmonella typhi and salmonella enterica can be identified by integrating probes for detecting salmonella serotype target genes viaB, tyv, filiC-alpha, fliCl, rfbJ, fliC2, invA and hilA on the same chip. The invention can rapidly and accurately carry out the preliminary screening and identification of salmonella and serotype thereof, greatly shortens detection time and is applicable to the requirement of high throughput detection.

The invention provides Lactobacillus salivarius M6, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) with the number of CGMCC 3505. The invention also provides a lactobacillus which can be mixed with animal feed or added into water, can be used together with antibiotics at the same time, and has antibiotic resistance. The strain can inhibit growth of Salmonella enterica, Escherichia coli and other pathogenic bacteria. The antibacterial composition of the Lactobacillus salivarius M6 can be used in drinking water, drinking water additives, feed and food additives of animals, human and animal medical composition, as well as drinks, drinking additives, foods, food additives and the like of humans. By implementation of the invention, pathogenic bacterium infection of animals or humans can be effectively prevented and treated, and the number of intestinal probiotics can be increased or maintained, so that the growth of pathogenic bacteria is inhibited, the dosage of antibiotics is reduced, and the aim of preventing disease infection of animals and humans can be achieved.

The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and/or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.

The present invention relates to novel peptide compounds derived from flagellin originating from Salmonella enterica that exhibit an in vivo immune adjuvant activity.

The purpose of this study was to test the efficacy of an oregano extract containing carvacrol and capyrlic acid blend by screening for inhibition and by conducting a preservative efficacy test, USP 51, in skin creams. Minimum inhibitory concentrations were found for Escherichia coli, Staphylococcus aureus, Pseudomonsas aeruginosa, Streptococcus sanguinis, Salmonella enterica, Candida albicans, and Aspergillus brasiliensis.

The invention relates to a pullorum disease agglutination antigen and a preparation method thereof and mainly relates to a bacterial strain which is salmonella pullorum standard strain C79-1 and a screened wild isolated strain S44. The wild isolated strain S44 of salmonella pullorum is classified and named as follows: salmonella enterica intestinal sub-salmonella pullorum, of which the Latin name is Salmonella enterica subsp. enterica pullorum, which is screened from the salmonella pullorum separated from chicken and which is collected at China General Microbiological Culture Collection Center with the collection No.: CGMCC No. 14258. The method provided by the invention is scientific and reasonable, stable in production and low in cost; the selected pullorum disease agglutination antigen production strain is high in antigenicity and low in aberration rate; and the prepared pullorum disease agglutination antigen product has the advantages of high sensibility, high specificity, quick diagnosis, easiness in observing agglutination effect, and the like.

Described herein is the identification of a novel Salmonella enterica serovar Enteritidis locus that serves as a marker for DNA-based identification of this bacterium. In addition, three primer pairs derived from this locus that may be used in a nucleotide detection method to detect the presence of the bacterium are also disclosed herein.

The present invention discloses a method for producing lactic acid bacteria agent and bacteriocin by using salted vegetable wastewater. The method comprises the production steps of pretreatment, centrifugal separation, blending fermentation, preparation of lactic acid bacteria agent and recovery of bacteriocin. The invention has simple operation, low production costs, environmental protection, low energy consumption, high added value, and important economic value and environmental value. The invention has the beneficial effects that: yield of lactobacillus cell is high, and the obtained lactic acid bacteria has significant inhibition effect on Escherichia coli, Salmonella enterica, Staphylococcus aureus and Listeria monocytogenes bacteria, and shows more significant inhibitory effect in an acidic environment.

The invention discloses applications of Phyllanthus emblica or Phyllanthus emblica and a Phyllanthus emblica composition in preparation of products for preventing and/or treating at least one of mastitis, diarrhea and porcine respiratory diseases, and further provides antibacterial effects of Phyllanthus emblica or Phyllanthus emblica extract and the Phyllanthus emblica composition, wherein the Phyllanthus emblica or Phyllanthus emblica extract and the Phyllanthus emblica composition can effectively inhibit the growth of one or a variety of bacteria selected from Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas, Salmonella choleraesuis, Escherichia coli, Group A beta-hemolytic streptococcus, Streptococcus suis, Bordetella, Pasteurella multocida, Salmonella enterica, Staphylococcus haemolyticus, Enterococcus faecalis and Erysipelothrix rhusiopathiae, and the effectiveness of the uses are proved through experiments so as to expanded the applications of Phyllanthus emblica andthe Phyllanthus emblica composition.

An aptamer-based solid-state electrochemical biosensor for label-free detection of Salmonella enterica serovars utilizing immobilized aptamers. The device is realized by forming a matrix array of parallel capacitors, thus allowing the realization of low-cost, portable, fully integrated devices. Protein-aptamer binding modulates the threshold voltage of a circuit, changing the impedance (capacitance) of the circuit. This circuit is further characterized by an electrode coded with a p-Si substrate, enhancing the affinity between the Salmonella outer membrane proteins (OMPs) and the aptamer. An aptamer embedded detection plate is configured within a testing lid device that fits a standard, commercially available polymer specimen jar. A sample is mixed with broth for incubation and cultivation of any present Salmonella bacteria to obtain acceptable concentration of the pathogen for testing. The information obtained can then be transmitted by wireless network.

The invention discloses a quadruple fluorescence PCR method for detecting four types of pathogenic bacteria. The four types of pathogenic bacteria are staphylococcus aureus, salmonella enterica, listeria monocytogenes and vibrio parahemolyticus. Four elements, namely sample DNA, a pair of universal primers and four probes, fluorescence PCR premix liquid and positive control are adopted in the method. The method comprises the following steps: designing the primers and the probes in accordance with 16S rRNA genes of the four types of bacteria, implementing amplification on a target sequence and exciting corresponding fluorescence signals; and preparing a kit from the to-be-detected sample DNA in accordance with a reagent formula and amplification conditions of the fluorescence PCR amplification; and specifically, the method comprises the following steps: establishing a quadruple fluorescence PCR primer system for detecting the four types of bacteria; establishing the quadruple fluorescence PCR kit for detecting the four types of bacteria; and determining the quadruple fluorescence PCR identification method for detecting the four types of bacteria. The method provided by the invention has the advantages of being low in standard error, short in detection time, and being capable of simultaneously detecting a plurality of target genes and reducing reagent cost; and the method is applicable to detection of pathogenic bacteria in food and cosmetics.

The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain and/or a non-viable attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain for use the treatment of cancer recurrence/progression. Preferably the cancer is bladder cancer.

The invention provides a method for constructing a gram-negative bacterium capable of expressing a gram-positive bacterium polysaccharide. The method comprises the following steps: transforming a low-copy expression plasmid of the gram-positive bacterium polysaccharide into an asd and rfbP gene-deletion gram-negative bacterium, screening by a balanced lethal system to obtain the gram-negative bacterium capable of producing the gram-positive bacterium polysaccharide. The invention also provides the gram-negative bacterium capable of producing the gram-positive bacterium polysaccharide prepared by the method. The invention also provides a mutant of Salmonella enterica serovar Typhimurium P0005, which is named as Salmonella enterica subsp. enterica serovar Typhimurium P0005, and has the CCTCC NO: M 2016344. The gram-negative bacterium can express the gram-positive bacterium polysaccharide, and the method provided by the invention does not contain any resistance marker and meets the biosafety requirements of subsequent vaccines and other application.

The invention belongs to the preparation field of animal vaccines, and particularly relates to a non-antibiotically screened animal growth promotion oral DNA vaccine as well as a preparation method and applications thereof. A somatostatin with a GMCSF cell gene and a hepatitis b surface antigen fusion gene GS/2SS are cloned to a plasmid vector pVAX1 for obtaining a middle plasmid pVAX-GS/2SS; an aspartic acid Beta-galactose dehydrogenase gene (asd) is used for replacing a kanamycin (Kan) gene in the middle plasmid pVAX-GS/2SS to obtain an eukaryotic expression plasmid pGS/2SS of the non-antibiotically screened somatostatin; and then the plasmid pGS/2SS is converted into a pig cholera salmonella C500 lack of asd and crp genes for obtaining the non-antibiotically screened animal growth promotion oral DNA vaccine. The pig cholera salmonella (Salmonella enterica sv. Choleraesuis) C500/pGS/2SS which comprises the eukaryotic expression plasmid of the somatostatin is preserved in the China Center for Type culture collection (CCTCC) and the preservation number thereof is CCTCC NO: M208194. The method also discloses the preparation method of the vaccine and the applications thereof in the aspect of promoting the growth of the animals.

The present invention provides live recombinant microorganisms such as prokaryote organisms, particularly enterobacteria, preferably Salmonella enterica, containing SEQ. ID. no. 1 and SEQ. ID. no. 2 capable of expressing VapG and/or VapA/VapG lipoproteins (SEQ. ID. no. 3 and SEQ. ID. no. 4), optionally in combination with other active ingredients, methods for preparing vaccine strains, antigens (SEQ. ID. no. 3 and SEQ. ID. no. 4) and vaccine compositions, preferably vectored vaccines. Additionally, the present patent application relates to the use of the vaccine vectors in the preparation of pharmaceutical compositions, particularly vaccines indicated for the prevention and/or treatment of infections by Rhodococcus equi, its antibodies and/or antisera, diagnostic kits and methods for the prophylaxis and/or treatment of infections by R. equi.

The invention discloses recombinant lysed Salmonella enterica and a construction method and application thereof. The elements introduced to genome of the recombinant lysed Salmonella enterica include:a mazE expression element including antitoxin gene mazE and its upstream promoter PBAD, and positive-negative regulator gene araC that encodes the promoter PBAD; an lacI expression element includinga gene lacI and its upstream promoter PBAD, and a positive-negative regulator gene araC that encodes the promoter PBAD; and an mazF expression element including toxin gene mazF and its upstream promoter Plac. The invention also discloses a construction method and application of the recombinant lysed Salmonella enterica. A Salmonella vector is modified through the combination of an arabinose promoter regulatory gene technology and an MazEF system so that programmed death occurs to the Salmonella vector due to immunostimulation; safety is good; allowing Salmonella to serve as a biosafe controllable polyvalent vaccine vector to deliver an exogenous antigen is guaranteed.

Disclosed is a method and associated device for the rapid identification of viable bacterial contaminants in food products. The method detects viable microbes by using a combined ATP-bioluminescence immunoassay. Escherichia coli O157:H7 and Salmonella enterica serovar Typhimurium were selected as target organisms in various matrices including ground beef homogenate, apple juice, milk, and phosphate-buffered saline. Specific antibodies were immobilized on the surface of well plates in which the sample matrices were incubated. The plates were washed, and the wells were incubated with BacTiter-Glo reagent in Mueller-Hinton II broth. Bioluminescent output was measured with a luminometer and signal-to-noise ratios were calculated. The LOD was not affected by the presence of non-target cells. A strong linear correlation was observed between the number of cells and luminescent output over 4 orders of magnitude. This method provides a means of simultaneously detecting and identifying viable pathogens in complex matrices.